These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8264818)

  • 1. [Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma].
    Thomas CM; Wobbes T; Bonfrer JM; Peterse JL; Nap M; Beex LV
    Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2354-7. PubMed ID: 8264818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor markers in the screening, diagnosis and treatment of patients with breast carcinoma].
    van Dalen A
    Ned Tijdschr Geneeskd; 1994 Jan; 138(2):96-7. PubMed ID: 8107911
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tumor markers in the diagnosis and therapy of intestinal neoplasms].
    Gräter H
    Schweiz Rundsch Med Prax; 1992 Jul; 81(31-32):943-4. PubMed ID: 1496207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mucoid carcinoma antigen--a new tumor marker].
    Bieglmayer C; Szepesi T; Neunteufel W
    Gynakol Rundsch; 1988; 28 Suppl 2():203-5. PubMed ID: 3234919
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CA 15.3, a marker of breast cancer].
    Ruibal A
    Med Clin (Barc); 1988 Sep; 91(9):341-3. PubMed ID: 3216756
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor markers in colorectal cancer.
    de Thibault de Boesinghe L
    J Belge Radiol; 1989 Oct; 72(5):415-7. PubMed ID: 2600057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers in breast cancer.
    van Dalen A
    Ann Chir Gynaecol; 1989; 78(1):54-64. PubMed ID: 2667449
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
    Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
    [No Abstract]   [Full Text] [Related]  

  • 12. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
    Jäger W
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Rodríguez CA; Cruz JJ; Martín T; Gómez A; Olaverri A; Hernández M
    Cancer; 2002 Aug; 95(3):670-1; author reply 671. PubMed ID: 12209762
    [No Abstract]   [Full Text] [Related]  

  • 14. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
    Quaranta M; Micelli G; Coviello M; Donadeo A; Lozupone A; Schittulli F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):35-8. PubMed ID: 2092146
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of carcinoembryonic antigen test in human mammary carcinoma.
    Batabyal SK; Ghosh SN; Roy NK; Mehrotra YN; Gupta A
    Indian J Pathol Microbiol; 1987 Oct; 30(4):407-12. PubMed ID: 3507401
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
    Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
    Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.